XBIO-015 / Xenetic Biosci - LARVOL DELTA

Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform (Xenetic Biosciences Press Release) - "Xenetic Biosciences...announced it has continued its collaboration with The Scripps Research Institute ('TSRI') to advance the development of the Company's development program evaluating the combination of systemic DNase I and CAR T-cell therapies...Xenetic's systemic DNase I candidate, XBIO-015, is currently in preclinical development in combination with CAR-T cell therapy for both hematologic and solid tumors....Xenetic continues to advance its DNase-based technology towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors."

Licensing / partnership • Lymphoma • Pancreatic Cancer

Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic Cancer (Xenetic Biosciences Press Release) - "Xenetic Biosciences...announced that its collaboration partner, PeriNess Ltd. (PeriNess), has informed the Company that Bnei Zion Medical Center has commenced patient dosing in an exploratory clinical study of systemic DNase I in combination with FOLFIRINOX for the first line treatment of unresectable, locally advanced or metastatic pancreatic cancer....PeriNess has informed the Company that the exploratory study is evaluating the safety, biomarker response, pharmacokinetics (PK) and clinical activity of DNase I in combination with first line regimen of FOLFIRINOX chemotherapy in patients with locally advanced or metastatic pancreatic cancer. All patients will receive intravenous infusions of DNase I on Days 1 and 8 of consecutive 14-day cycles. Safety will be continuously evaluated until the end of the study."

Trial status • Pancreatic Cancer

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma (Xenetic Biosciences Press Release) - "Xenetic Biosciences, Inc...announced that its collaboration partner, PeriNess Ltd. ('PeriNess'), has entered into a Clinical Study Agreement (the 'Agreement') to support an exploratory clinical study of Xenetic's systemic DNase I candidate, XBIO-015, in patients with relapsed/refractory osteosarcoma and Ewing sarcoma...'The primary objective of this study is to explore safety and tolerability in patients with relapsed/refractory osteosarcoma or Ewing sarcoma receiving XBIO-015 in combination with relapsed chemotherapy regimens. Secondary objectives include efficacy to be evaluated by the measure of objective response rate and progression-free survival.'"

Licensing / partnership • New trial • Ewing Sarcoma • Osteosarcoma

Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program (Xenetic Biosciences Press Release) - "Xenetic Biosciences, Inc...announced it has entered into a Clinical Trial Services Agreement (the 'Agreement') with the Israel-based biotechnology company PeriNess Ltd. ('PeriNess') to advance the Company's development program for its systemic DNase I candidate in combination with chemotherapy and immunotherapy platforms for the treatment of pancreatic carcinoma, colorectal cancer and other locally advanced or metastatic solid tumors toward exploratory clinical studies....Under the terms of the Agreement, PeriNess will lead in the regulatory approval, operational execution and management of potential exploratory, investigator initiated studies of recombinant DNase as an adjunctive treatment in patients with pancreatic carcinoma and other locally advanced or metastatic solid tumors receiving chemotherapy and immunotherapy in Israeli medical centers."

Commercial • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis (Xenetic Biosciences Press Release) - "The poster...was presented on behalf of the Company by Alexey Stepanov...at the AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and Macroenvironment in Cancer, held November 17-20, 2024, in Boston.....Key Highlights: Co-administration of single injection of DNase I (10 mg/kg) with murine EGFR-CAR T cells demonstrated to significantly suppress metastatic tumor burden, decreases the number of metastatic foci, and substantially prolongs survival compared to the CAR T cell monotherapy group; Degrading of NETs by DNase I increases the amount of tumor-infiltrating T and CAR T cells and reduces the immunosuppressive effects of the TME; Tumor immune cell infiltrate analysis revealed that the CD8 population of tumor-infiltrating CAR T cells from the DNase I treated group have lower expression of PD-1 and TIM-3 exhaustion markers."

Preclinical • Melanoma • Oncology • Skin Cancer • Solid Tumor

Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models (Xenetic Biosciences Press Release) - "Data demonstrates beneficial effects of targeting NETs with systemic DNase I in models of primary tumor and metastatic CRC, improving the efficacy of CTLA-4 immune checkpoint blockade; Both published and newer data suggests that DNase I impedes neutrophil tumor infiltration, promotes CD4 and CD8 T cell infiltration, and enhances intratumoral T cell activation; DNase I plus 𝛼-CTLA-4 combination therapy results in tumor growth inhibition, several CRs and enhanced survival in mice bearing CT26 or Colon26 MSS/MMRp CRC tumors; Dose response evaluations of DNase I combined with 𝛼-CTLA-4, examining both route and frequency of administration was performed; DNase I plus 𝛼-CTLA-4 combination therapy resulted in complete responses (CRs) in mice bearing either CT26 or Colon26 tumors."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024 (Xenetic Biosciences Press Release) - "Xenetic Biosciences, Inc...announced its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6-10, 2024, in Houston, Texas and virtually."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor